反应详情

The title compound was prepared following the procedure described for Example 94, but starting from 4-(5-(1-(2-fluorophenyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-1,2,4-oxadiazol-3-yl)benzaldehyde, obtained as described in Example 113, Step 1, (200 mg; 0.48 mmol) and (1R,3S)-3-aminocyclopentanecarboxylic acid (125 mg; 0.97 mmol), to give Example 169 as a white solid. 1H NMR: (DMSO-d6, 400 MHz) δ 8.76-8.71 (2H, m), 7.98 (2H, d, J=8.0 Hz), 7.93-7.85 (1H, m), 7.76-7.68 (1H, m), 7.64-7.58 (4H, m), 7.53-7.46 (2H, m), 3.97 (1H, d, J=13.8 Hz), 3.89 (1H, d, J=13.8 Hz), 3.27 (1H, t, J=4.8 Hz), 2.76-2.67 (1H, m), 1.94-1.73 (6H, m). LC/MS (Method C): 524 (M+H)+. HPLC (Method F) Rt 2.86 min (Purity: 96.2%).

1. customobtained